Top Markets
Coin of the day
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Hisse Senetlerindeki Sıralama #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Hisse Fiyatı
$50.82
Son senkronizasyon: 2026-08-11
Piyasa Değeri
$102.09M
Değişim (1 gün)
1.90%
Değişim (1 yıl)
-
Ülke
US
Ticaret Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Kategori

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) için temettü verimi geçmişi
Hemab Therapeutics Holdings, Inc. Common Stock (hisse sembolü: COAG) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin temettü verimi (TTM)
Şirket Temettü Verimi Ülke
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH